Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20547754 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Alan JK, et al. (2010) Regulation of the Rho family small GTPase Wrch-1/RhoU by C-terminal tyrosine phosphorylation requires Src. Mol Cell Biol 30, 4324-38 20547754
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T423-p - PAK1 (human) ▲
Orthologous residues
PAK1 (human): T423‑p, PAK1 (mouse): T423‑p, PAK1 (rat): T422‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RhoU (human) decrease RHOU Y254E mutant
RhoU (human) increase RHOU wt or Y254F mutant

Y402-p - Pyk2 (human) ▲
Orthologous residues
Pyk2 (human): Y402‑p, Pyk2 iso2 (human): Y402‑p, Pyk2 (mouse): Y402‑p, Pyk2 (rat): Y402‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RhoU (human) decrease RHOU Y254E mutant
RhoU (human) increase RHOU wt or Y254F mutant

Y254-p - RhoU (human) ▲
Orthologous residues
RhoU (human): Y254‑p, RhoU (mouse): Y257‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  MDCKII (epithelial), MEF (fibroblast), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) transfection of constitutively active enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
SU6656 serum inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  inhibition, intracellular localization, molecular association, regulation
 Effect of modification (process):  cell growth, altered, cytoskeletal reorganization
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PAK1 (human) PBD Disrupts microscopy-colocalization


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.